Testing effectiveness (Phase 2)Ended earlyNCT03300843
What this trial is testing
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Who this might be right for
MelanomaGastrointestinal CancerBreast Cancer+2 more
National Cancer Institute (NCI) 1